flumazenil has been researched along with Alcohol Withdrawal Associated Autonomic Hyperactivity in 2 studies
Flumazenil: A potent benzodiazepine receptor antagonist. Since it reverses the sedative and other actions of benzodiazepines, it has been suggested as an antidote to benzodiazepine overdoses.
flumazenil : An organic heterotricyclic compound that is 5,6-dihydro-4H-imidazo[1,5-a][1,4]benzodiazepine which is substituted at positions 3, 5, 6, and 8 by ethoxycarbonyl, methyl, oxo, and fluoro groups, respectively. It is used as an antidote to benzodiazepine overdose.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events." | 5.40 | Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. ( Adkins, AR; Burkhart, KK; Donovan, JW; Haggerty, DA; Hieger, MA; Moore, PW; Rasimas, JJ; Waskin, JA; Wert, Y, 2014) |
| " For patients being treated for alcohol withdrawal, flumazenil can diagnose and treat benzodiazepine delirium without precipitating serious or life-threatening adverse events." | 1.40 | Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center. ( Adkins, AR; Burkhart, KK; Donovan, JW; Haggerty, DA; Hieger, MA; Moore, PW; Rasimas, JJ; Waskin, JA; Wert, Y, 2014) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nelson, LS | 1 |
| Moore, PW | 1 |
| Donovan, JW | 1 |
| Burkhart, KK | 1 |
| Waskin, JA | 1 |
| Hieger, MA | 1 |
| Adkins, AR | 1 |
| Wert, Y | 1 |
| Haggerty, DA | 1 |
| Rasimas, JJ | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Effect of Flumazenil on Hypoactive Delirium in the ICU: A Double-Blind, Placebo-Controlled Pilot Study[NCT02899156] | Phase 4 | 22 participants (Actual) | Interventional | 2016-03-31 | Terminated (stopped due to A planned interim analysis led to the trial being stopped early based on the observed size effect and power analysis.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
average duration of time patient was randomized to each infusion up to 72 hours (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | hours (Mean) |
|---|---|
| Flumazenil Group | 54.8 |
| Placebo Group | 58.2 |
average maximum rate (ml/hr) during the 72 hours after study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | milliliters per hour (Mean) |
|---|---|
| Flumazenil Group | 5 |
| Placebo Group | 5.2 |
length of time that the patient was admitted to an intensive care unit service during the hospital stay (NCT02899156)
Timeframe: duration of admission to the intensive care unit
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 7.8 |
| Placebo Group | 7 |
Defined by the number of days in the 14-day period after randomization that the patient was alive and not delirious (i.e. CAM-ICU negative). Zero delirium-free days will be observed for patients that die within the 14-day period. (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | days (Median) |
|---|---|
| Flumazenil Group | 12.7 |
| Placebo Group | 9.2 |
number of days within the first 28 days after enrollment that the patient was free from needing mechanical ventilation (NCT02899156)
Timeframe: up to 28 days after randomization
| Intervention | days (Mean) |
|---|---|
| Flumazenil Group | 23.6 |
| Placebo Group | 24.9 |
defined by the proportion of patients who were delirium free at 14 days after randomization (NCT02899156)
Timeframe: up to 14 days after randomization
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 9 |
| Placebo Group | 7 |
number of times that a RASS score of + 2 to +4 occurred that did not resolve with decreasing study infusion (NCT02899156)
Timeframe: up to 72 hours after the start of the infusion
| Intervention | Participants (Count of Participants) |
|---|---|
| Flumazenil Group | 0 |
| Placebo Group | 0 |
2 other studies available for flumazenil and Alcohol Withdrawal Associated Autonomic Hyperactivity
| Article | Year |
|---|---|
Alcohol withdrawal and flumazenil: not for the faint of heart.
Topics: Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcohol Withdrawal Seizures; Antidotes; Delirium; D | 2014 |
Safety and efficacy of flumazenil for reversal of iatrogenic benzodiazepine-associated delirium toxicity during treatment of alcohol withdrawal, a retrospective review at one center.
Topics: Adult; Aged; Aged, 80 and over; Alcohol Deterrents; Alcohol Withdrawal Delirium; Alcohol Withdrawal | 2014 |